A detailed history of Stifel Financial Corp transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 624,876 shares of EDIT stock, worth $1.66 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
624,876
Previous 453,220 37.87%
Holding current value
$1.66 Million
Previous $2.12 Million 0.66%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.39 - $5.96 $581,913 - $1.02 Million
171,656 Added 37.87%
624,876 $2.13 Million
Q2 2024

Aug 13, 2024

BUY
$4.67 - $7.28 $1.03 Million - $1.6 Million
219,517 Added 93.93%
453,220 $2.12 Million
Q1 2024

May 13, 2024

BUY
$7.03 - $11.07 $570,062 - $897,666
81,090 Added 53.13%
233,703 $1.73 Million
Q4 2023

Feb 12, 2024

BUY
$6.25 - $11.11 $4,100 - $7,288
656 Added 0.43%
152,613 $1.55 Million
Q3 2023

Nov 13, 2023

BUY
$6.92 - $9.31 $25,811 - $34,726
3,730 Added 2.52%
151,957 $1.19 Million
Q2 2023

Aug 14, 2023

BUY
$6.36 - $11.47 $37,581 - $67,776
5,909 Added 4.15%
148,227 $1.22 Million
Q1 2023

May 12, 2023

BUY
$7.03 - $11.53 $576,424 - $945,402
81,995 Added 135.93%
142,318 $1.03 Million
Q4 2022

Feb 13, 2023

SELL
$8.32 - $13.21 $272,596 - $432,812
-32,764 Reduced 35.2%
60,323 $535,000
Q3 2022

Nov 14, 2022

BUY
$12.16 - $19.42 $32,892 - $52,531
2,705 Added 2.99%
93,087 $1.14 Million
Q2 2022

Aug 15, 2022

BUY
$9.99 - $21.35 $264,774 - $565,860
26,504 Added 41.49%
90,382 $1.07 Million
Q1 2022

May 13, 2022

BUY
$14.08 - $27.63 $719,459 - $1.41 Million
51,098 Added 399.83%
63,878 $1.22 Million
Q4 2021

Feb 14, 2022

SELL
$26.55 - $40.57 $71,100 - $108,646
-2,678 Reduced 17.32%
12,780 $340,000
Q3 2021

Nov 15, 2021

SELL
$39.27 - $72.94 $2.48 Million - $4.6 Million
-63,085 Reduced 80.32%
15,458 $635,000
Q2 2021

Aug 13, 2021

BUY
$31.29 - $56.64 $297,442 - $538,419
9,506 Added 13.77%
78,543 $4.45 Million
Q1 2021

May 14, 2021

BUY
$39.71 - $90.58 $2.23 Million - $5.1 Million
56,269 Added 440.7%
69,037 $2.9 Million
Q4 2020

Feb 12, 2021

BUY
$27.07 - $84.35 $345,629 - $1.08 Million
12,768 New
12,768 $895,000
Q1 2020

May 14, 2020

SELL
$14.88 - $32.78 $117,715 - $259,322
-7,911 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$19.49 - $32.63 $202,033 - $338,242
-10,366 Reduced 56.72%
7,911 $234,000
Q3 2019

Nov 13, 2019

SELL
$22.49 - $26.81 $320,617 - $382,203
-14,256 Reduced 43.82%
18,277 $418,000
Q2 2019

Aug 14, 2019

BUY
$20.48 - $27.76 $23,408 - $31,729
1,143 Added 3.64%
32,533 $795,000
Q1 2019

May 14, 2019

BUY
$19.43 - $26.41 $609,907 - $829,009
31,390 New
31,390 $762,000
Q4 2018

Feb 13, 2019

SELL
$18.19 - $31.79 $146,884 - $256,704
-8,075 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$27.65 - $38.39 $29,723 - $41,269
1,075 Added 15.36%
8,075 $257,000
Q2 2018

Aug 14, 2018

SELL
$31.4 - $41.01 $188,086 - $245,649
-5,990 Reduced 46.11%
7,000 $256,000
Q1 2018

May 11, 2018

BUY
$29.84 - $44.08 $158,450 - $234,064
5,310 Added 69.14%
12,990 $433,000
Q4 2017

Feb 14, 2018

BUY
$21.89 - $31.34 $168,115 - $240,691
7,680
7,680 $236,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $183M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.